Steven Cohen Cardiff Oncology, Inc. Transaction History
Point72 Asset Management, L.P.
- $42.2 Billion
- Q4 2024
A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Cardiff Oncology, Inc. stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 508,438 shares of CRDF stock, worth $2.42 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
508,438Holding current value
$2.42 Million% of portfolio
0.01%Shares
3 transactions
Others Institutions Holding CRDF
# of Institutions
125Shares Held
25.3MCall Options Held
866KPut Options Held
203K-
Commodore Capital LP New York, NY5.38MShares$25.6 Million2.34% of portfolio
-
Black Rock Inc. New York, NY2.63MShares$12.5 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.28MShares$10.9 Million0.0% of portfolio
-
Orbimed Advisors LLC San Diego, CA1.54MShares$7.31 Million0.18% of portfolio
-
Acorn Capital Advisors, LLC New York, NY1.44MShares$6.85 Million3.38% of portfolio
About Cardiff Oncology, Inc.
- Ticker CRDF
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,334,900
- Market Cap $206M
- Description
- Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...